ML385: A Selective NRF2 Inhibitor for Cancer and Oxidative Stress Research

Executive Summary: ML385 (CAS 846557-71-9) is a potent, selective small molecule inhibitor of the transcription factor NRF2, widely used in cancer and redox biology research (APExBIO ML385). With an IC50 of 1.9 μM, ML385 effectively downregulates NRF2-dependent gene expression in dose- and time-dependent manners (Wang et al., 2024). In non-small cell lung cancer (NSCLC) models, ML385 reduces tumor growth and metastasis, especially when combined with chemotherapeutics like carboplatin. The compound is insoluble in ethanol and water but achieves ≥13.33 mg/mL solubility in DMSO, supporting diverse experimental workflows. Recent studies confirm that ML385 blocks NRF2-mediated neuroprotection and ferroptosis resistance, validating its specificity and translational relevance.

Biological Rationale

NRF2 (Nuclear factor erythroid 2-related factor 2) is a transcription factor that regulates cellular antioxidant and detoxification responses (Wang et al., 2024). It controls the expression of genes involved in oxidative stress response, redox homeostasis, and multidrug resistance. Aberrant NRF2 activation is implicated in cancer progression, therapeutic resistance, and diseases involving oxidative damage. In NSCLC, persistent NRF2 signaling contributes to chemoresistance and tumor survival. Inhibiting NRF2 has emerged as a strategy to sensitize cancer cells to standard therapies and dissect redox signaling mechanisms (Related article: ML385 in NSCLC—this article extends the mechanistic context and includes recent neuroprotection data).

Mechanism of Action of ML385

ML385 is a selective, small molecule inhibitor targeting the transcriptional activity of NRF2. It binds directly to the Neh1 domain of NRF2, preventing its interaction with DNA and coactivators. This action suppresses the transcription of NRF2-dependent genes, including those encoding phase II detoxification enzymes (e.g., HO-1, NQO1, GPX4). In A549 NSCLC cell lines, ML385 produces dose-dependent inhibition of NRF2 target gene expression within 24 hours at concentrations as low as 1.9 μM (IC50). The inhibition is reversible and does not cause significant off-target cytotoxicity under standard in vitro conditions (APExBIO product data).

Evidence & Benchmarks

• ML385 exhibits a selective IC50 of 1.9 μM for NRF2 inhibition in A549 NSCLC cells (APExBIO).
• Treatment with ML385 significantly reduces NRF2-dependent gene expression (HO-1, GPX4) in vitro and in vivo (Wang et al., 2024, DOI).
• In NSCLC mouse models, ML385 alone decreases tumor growth rates and inhibits metastasis; combination with carboplatin further enhances efficacy (APExBIO).
• ML385 blocks the neuroprotective effects of artemisinin in type 2 diabetes mellitus (T2DM) mouse models by inhibiting hippocampal NRF2 activation and increasing neuronal ferroptosis (Wang et al., 2024, DOI).
• ML385 is insoluble in ethanol/water but soluble at ≥13.33 mg/mL in DMSO, supporting its use in cell-based and animal studies (APExBIO).
• NRF2 inhibition with ML385 is dose- and time-dependent, reversible, and does not significantly affect non-NRF2 pathways under standard experimental conditions (Related article: Protocol Q&A—this article adds new in vivo context and clarifies neuroprotection boundaries).

Applications, Limits & Misconceptions

ML385 is primarily utilized in oncology, neuroscience, and redox biology to dissect NRF2 signaling pathways, study oxidative stress responses, and model chemoresistance mechanisms. It is frequently applied in:

• Non-small cell lung cancer research and combination therapy models.
• Studies of ferroptosis, especially in neurodegeneration and diabetes-related cognitive impairment.
• Functional genomics for validating NRF2 gene targets and regulatory networks.
• Screening for compounds that synergize with or antagonize NRF2 inhibition.

Common Pitfalls or Misconceptions

• ML385 is not suitable for in vivo use with ethanol or water as a vehicle—use DMSO for solubilization to achieve effective dosing (APExBIO).
• Effects are NRF2-specific—ML385 does not broadly suppress transcription or induce cytotoxicity at recommended concentrations (Related article: Cancer focus—this article expands on ferroptosis and neuroprotection).
• ML385 is not a direct antioxidant or iron chelator; its effects are mediated through transcriptional inhibition, not direct ROS scavenging.
• Long-term storage of ML385 solutions can compromise potency—prepare fresh solutions and store the dry compound at -20°C for stability.
• Not effective in NRF2-null cell lines or knockout animal models; the inhibitor requires the presence of functional NRF2 protein.

Workflow Integration & Parameters

ML385 (SKU B8300) from APExBIO is supplied as a powder and should be dissolved in DMSO to a working stock of at least 13.33 mg/mL. Recommended storage is -20°C. For in vitro studies, treat cells with 1–10 μM for 24–72 hours, monitoring NRF2 target gene expression by qPCR or Western blot. For in vivo models, follow published protocols (see Wang et al., 2024), using validated dosing regimens and appropriate controls. Avoid repeated freeze-thaw cycles of solutions. For protocol optimization, see scenario-driven guides (internal guide—this article incorporates new neurodegeneration benchmarks).

Conclusion & Outlook

ML385 is a validated, selective NRF2 inhibitor that enables targeted dissection of antioxidant response pathways in cancer, neurodegeneration, and redox biology. Its specificity and robust preclinical evidence support its use in translational research, including combination therapy and ferroptosis modulation. Continuing research will expand its utility in disease models beyond cancer, with careful attention to vehicle choice and experimental context. For further details, visit the ML385 product page at APExBIO.